Table 2 Crude and corrected sensitivity, specificity, PPV and NPV for CIN2+, by test
From: Different cervical cancer screening approaches in a Chinese multicentre study
Sensitivity | Specificity | PPV | NPV | ||||||
|---|---|---|---|---|---|---|---|---|---|
Tests | Status | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI |
VIA | Crude | 42.9 | (27.7–59.0) | 89.4 | (87.8–90.8) | 8.7 | (5.2–13.4) | 98.5 | (97.8–99.0) |
Corrected | 37.1 | (26.4–49.3) | 89.4 | (87.9–90.8) | 10.0 | (6.7–14.6) | 97.8 | (97.1–98.4) | |
Digital colposcopy | Crude | 60.8 | (48.8–72.0) | 85.1 | (83.6–86.5) | 10.8 | (8.0–14.2) | 98.6 | (98.1–99.1) |
Corrected | 54.1 | (44.6–63.3) | 85.1 | (83.7–86.5) | 11.7 | (9.0–15.1) | 98.1 | (97.5–98.5) | |
LBC⩾ASCUS | Crude | 93.2 | (84.9–97.8) | 85.1 | (83.7–86.5) | 15.7 | (12.4–19.5) | 99.8 | (99.5–99.9) |
Corrected | 86.9 | (81.1–91.1) | 85.4 | (84.0–86.7) | 17.8 | (14.7–21.5) | 99.4 | (99.2–99.6) | |
HC2 | Crude | 90.5 | (81.5–96.1) | 85.9 | (84.5–87.2) | 16.0 | (12.6–19.9) | 99.7 | (99.3–99.9) |
Corrected | 90.4 | (83.3–94.7) | 86.4 | (85.0–87.7) | 19.5 | (16.3–23.2) | 99.6 | (99.3–99.8) | |
HC2 triage of ASCUS | Crude | 90.5 | (81.5–96.1) | 93.5 | (92.4–94.4) | 29.3 | (23.5–35.6) | 99.7 | (99.4–99.9) |
Corrected | 84.0 | (77.4–88.9) | 93.8 | (92.8–94.7) | 33.1 | (27.6–39.0) | 99.4 | (99.1–99.6) | |
LBC⩾ASCUS or HC2 | Crude | 95.9 | (88.6–99.2) | 76.9 | (75.2–78.5) | 11.0 | (8.7–13.7) | 99.8 | (99.5–100.0) |
Corrected | 95.5 | (90.0–98.1) | 77.3 | (75.7–78.9) | 13.3 | (11.1–15.9) | 99.8 | (99.5–99.9) | |
